PDGFRA activating mutations in gastrointestinal stromal tumors.

Article Details

Citation

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA

PDGFRA activating mutations in gastrointestinal stromal tumors.

Science. 2003 Jan 31;299(5607):708-10. Epub 2003 Jan 9.

PubMed ID
12522257 [ View in PubMed
]
Abstract

Most gastrointestinal stromal tumors (GISTs) have activating mutations in the KIT receptor tyrosine kinase, and most patients with GISTs respond well to Gleevec, which inhibits KIT kinase activity. Here we show that approximately 35% (14 of 40) of GISTs lacking KIT mutations have intragenic activation mutations in the related receptor tyrosine kinase, platelet-derived growth factor receptor alpha (PDGFRA). Tumors expressing KIT or PDGFRA oncoproteins were indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression. Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs.

DrugBank Data that Cites this Article

Polypeptides
NameUniProt ID
Platelet-derived growth factor receptor alphaP16234Details